Market capitalization | $33.86m |
Enterprise Value | $41.31m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.35 |
P/S ratio (TTM) P/S ratio | 0.29 |
P/B ratio (TTM) P/B ratio | 0.49 |
Revenue growth (TTM) Revenue growth | -9.94% |
Revenue (TTM) Revenue | $116.43m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
8 Analysts have issued a Outset Medical Inc forecast:
8 Analysts have issued a Outset Medical Inc forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -34 -34 |
22%
22%
|
|
Depreciation and Amortization | 1.47 1.47 |
19%
19%
|
|
Stock Compensation | 9.82 9.82 |
3%
3%
|
|
Operating Cash Flow | -33 -33 |
18%
18%
|
|
Investments | 0.12 0.12 |
85%
85%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -33 -33 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.
Head office | United States |
CEO | Leslie Trigg |
Employees | 480 |
Founded | 2003 |
Website | www.outsetmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.